🇺🇸 FDA
Pipeline program

SB-728mR-HSPC Infusion 3 days following busulfan conditioning

14017

Phase 1 gene_therapy active

Quick answer

SB-728mR-HSPC Infusion 3 days following busulfan conditioning for HIV is a Phase 1 program (gene_therapy) at SANGAMO THERAPEUTICS, INC with 1 ClinicalTrials.gov record(s).

Program details

Company
SANGAMO THERAPEUTICS, INC
Indication
HIV
Phase
Phase 1
Modality
gene_therapy
Status
active

Clinical trials